A double-blind, randomized, placebo-controlled, multicenter study investigating the efficacy and tolerability of angeliq(drospirenon2mg and estradiol 1mg) in postmenopausal korean women with vasomotor symptoms over 3, 28 day treatment cycle.
Phase of Trial: Phase III
Latest Information Update: 06 Jan 2015
At a glance
- Drugs Estradiol/drospirenone (Primary)
- Indications Hot flashes
- Focus Therapeutic Use
- Sponsors Bayer
- 03 Mar 2009 Actual patient number (72) added as reported by ClinicalTrials.gov.
- 03 Mar 2009 Bayer Schering Pharma added as trial affiliate as reported by ClinicalTrials.gov.
- 22 Apr 2008 New trial record.